Antibody-Drug Conjugates Market Size, Share, Revenue Analysis 2032

• Chapter 1. Preface
  • 1.1. Report Description and Scope
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology
• Chapter 2. Executive Summary
  • 2.1. Antibody-Drug Conjugates Market, 2024-2032 (USD Billion)
  • 2.2. Antibody-Drug Conjugates Market: Snapshot
• Chapter 3. Antibody-Drug Conjugates Market - Industry Analysis
  • 3.1. Antibody-Drug Conjugates Market: Market Dynamics
  • 3.2. Market Drivers
    • 3.2.1. Driver 1
    • 3.2.2. Driver 2
  • 3.3. Restraints
    • 3.3.1. Restraint 1
    • 3.3.2. Restraint 2
  • 3.4. Opportunity
    • 3.4.1. Government funding and support
  • 3.5. Porter's Five Forces Analysis
  • 3.6. Market Attractiveness Analysis
    • 3.6.1. Market attractiveness analysis By Application
    • 3.6.2. Market attractiveness analysis By Technology
    • 3.6.3. Market attractiveness analysis by Region
• Chapter 4. Antibody-Drug Conjugates Market- Competitive Landscape
  • 4.1. Company market share analysis
    • 4.1.1. Global Antibody-Drug Conjugates Market: company market share, 2024
  • 4.2. Strategic development
    • 4.2.1. Acquisitions & mergers
    • 4.2.2. New Application launches
    • 4.2.3. Agreements, partnerships, collaborations and joint ventures
    • 4.2.4. Research and development and Regional expansion
  • 4.3. Price trend analysis
• Chapter 5. Global Antibody-Drug Conjugates Market - By Application Analysis
  • 5.1. Global Antibody-Drug Conjugates Market overview: By Application
    • 5.1.1. Global Antibody-Drug Conjugates Marketshare, By Application,2024 and 2032
  • 5.2. Blood Cancer
    • 5.2.1. Global Antibody-Drug Conjugates Market by Blood Cancer, 2024-2032 (USD Billion)
  • 5.3. Leukemia
    • 5.3.1. Global Antibody-Drug Conjugates Market by Leukemia, 2024-2032 (USD Billion)
  • 5.4. Lymphoma
    • 5.4.1. Global Antibody-Drug Conjugates Market by Lymphoma, 2024-2032 (USD Billion)
  • 5.5. Breast Cancer
    • 5.5.1. Global Antibody-Drug Conjugates Market by Breast Cancer, 2024-2032 (USD Billion)
  • 5.6. Ovarian Cancer
    • 5.6.1. Global Antibody-Drug Conjugates Market by Ovarian Cancer, 2024-2032 (USD Billion)
  • 5.7. Lung Cancer
    • 5.7.1. Global Antibody-Drug Conjugates Market by Lung Cancer, 2024-2032 (USD Billion)
  • 5.8. Brain Tumor
    • 5.8.1. Global Antibody-Drug Conjugates Market by Brain Tumor, 2024-2032 (USD Billion)
• Chapter 6. Global Antibody-Drug Conjugates Market -Technology Analysis
  • 6.1. Global Antibody-Drug Conjugates Market overview: By Technology
    • 6.1.1. Global Antibody-Drug Conjugates Market share, By Technology, 2024 and 2032
  • 6.2. Cleavable Linker
    • 6.2.1. Global Antibody-Drug Conjugates Market By Cleavable Linker, 2024-2032 (USD Billion)
  • 6.3. Non-cleavable Linker
    • 6.3.1. Global Antibody-Drug Conjugates MarketBy Non-cleavable Linker, 2024-2032 (USD Billion)
• Chapter 7. Global Antibody-Drug Conjugates Market - Regional Analysis
  • 7.1. Global Antibody-Drug Conjugates Market overview: by Region
    • 7.1.1. Global Antibody-Drug Conjugates Marketshare, by Region, 2024 and 2032
  • 7.2. North America
    • 7.2.1. North America Antibody-Drug Conjugates Market, 2024-2032 (USD Billion)
    • 7.2.2. North America Antibody-Drug Conjugates Market revenue, By Application,2024-2032 (USD Billion)
    • 7.2.3. North America Antibody-Drug Conjugates Market revenue, By Technology, 2024-2032 (USD Billion)
    • 7.2.4. The U.S.
      • 7.2.4.1. The U.S.Antibody-Drug Conjugates Marketrevenue, By Application,2024-2032 (USD Billion)
      • 7.2.4.2. The U.S.Antibody-Drug Conjugates Market revenue, By Technology, 2024-2032 (USD Billion)
    • 7.2.5. Rest of North America
      • 7.2.5.1. Rest of North America Antibody-Drug Conjugates Market revenue, By Application,2024-2032 (USD Billion)
      • 7.2.5.2. Rest of North America Antibody-Drug Conjugates Marketrevenue, By Technology, 2024-2032 (USD Billion)
  • 7.3. Europe
    • 7.3.1. Europe Antibody-Drug Conjugates Market, 2024-2032 (USD Billion)
    • 7.3.2. Europe Antibody-Drug Conjugates Market revenue, By Application,2024-2032 (USD Billion)
    • 7.3.3. Europe Antibody-Drug Conjugates Market revenue, By Technology, 2024-2032 (USD Billion)
    • 7.3.4. UK
      • 7.3.4.1. U.K.Antibody-Drug Conjugates Marketrevenue, By Application,2024-2032 (USD Billion)
      • 7.3.4.2. U.K.Antibody-Drug Conjugates Market revenue, By Technology, 2024-2032 (USD Billion)
    • 7.3.5. France
      • 7.3.5.1. France Antibody-Drug Conjugates Marketrevenue, By Application,2024-2032 (USD Billion)
      • 7.3.5.2. France Antibody-Drug Conjugates Marketrevenue, By Technology, 2024-2032 (USD Billion)
    • 7.3.6. Germany
      • 7.3.6.1. Germany Antibody-Drug Conjugates Marketrevenue, By Application,2024-2032 (USD Billion)
      • 7.3.6.2. Germany Antibody-Drug Conjugates Market revenue, By Technology, 2024-2032 (USD Billion)
    • 7.3.7. Rest of Europe
      • 7.3.7.1. Rest of EuropeAntibody-Drug Conjugates Marketrevenue, By Application,2024-2032 (USD Billion)
      • 7.3.7.2. Rest of EuropeAntibody-Drug Conjugates Market revenue, By Technology, 2024-2032 (USD Billion)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Antibody-Drug Conjugates Market, 2024-2032 (USD Billion)
    • 7.4.2. Asia Pacific Antibody-Drug Conjugates Marketrevenue, By Application,2024-2032 (USD Billion)
    • 7.4.3. Asia Pacific Antibody-Drug Conjugates Market revenue, By Technology, 2024-2032 (USD Billion)
    • 7.4.4. China
      • 7.4.4.1. China Antibody-Drug Conjugates Market revenue, By Application,2024-2032 (USD Billion)
      • 7.4.4.2. China Antibody-Drug Conjugates Marketrevenue, By Technology, 2024-2032 (USD Billion)
    • 7.4.5. Japan
      • 7.4.5.1. Japan Antibody-Drug Conjugates Market revenue, By Application,2024-2032 (USD Billion)
      • 7.4.5.2. Japan Antibody-Drug Conjugates Marketrevenue, By Technology, 2024-2032 (USD Billion)
    • 7.4.6. India
      • 7.4.6.1. India Antibody-Drug Conjugates Market revenue, By Application,2024-2032 (USD Billion)
      • 7.4.6.2. India Antibody-Drug Conjugates Market revenue, By Technology, 2024-2032 (USD Billion)
    • 7.4.7. Rest of Asia Pacific
      • 7.4.7.1. Rest of Asia Pacific Antibody-Drug Conjugates Marketrevenue, By Application,2024-2032 (USD Billion)
      • 7.4.7.2. Rest of Asia Pacific Antibody-Drug Conjugates Market revenue, By Technology, 2024-2032 (USD Billion)
  • 7.5. Latin America
    • 7.5.1. Latin America Antibody-Drug Conjugates Market, 2024-2032 (USD Billion)
    • 7.5.2. Latin America Antibody-Drug Conjugates Marketrevenue, By Application,2024-2032 (USD Billion)
    • 7.5.3. Latin America Antibody-Drug Conjugates Marketrevenue, By Technology, 2024-2032 (USD Billion)
    • 7.5.4. Brazil
      • 7.5.4.1. Brazil Antibody-Drug Conjugates Marketrevenue, By Application,2024-2032 (USD Billion)
      • 7.5.4.2. Brazil Antibody-Drug Conjugates Marketrevenue, By Technology, 2024-2032 (USD Billion)
    • 7.5.5. Rest of LatinAmerica
      • 7.5.5.1. Rest of LatinAmerica Antibody-Drug Conjugates Market revenue, By Application,2024-2032 (USD Billion)
      • 7.5.5.2. Rest of LatinAmerica Antibody-Drug Conjugates Market revenue, By Technology, 2024-2032 (USD Billion)
  • 7.6. The Middle East and Africa
    • 7.6.1. The Middle East and Africa Antibody-Drug Conjugates Market, 2024-2032 (USD Billion)
    • 7.6.2. The Middle East and Africa Antibody-Drug Conjugates Market revenue, By Application,2024-2032 (USD Billion)
    • 7.6.3. The Middle East and Africa Antibody-Drug Conjugates Marketrevenue, By Technology, 2024-2032 (USD Billion)
• Chapter 8. Company Profiles
  • 8.1. AbbVie Inc.
    • 8.1.1. Overview
    • 8.1.2. Financials
    • 8.1.3. Application Portfolio
    • 8.1.4. Business Strategy
    • 8.1.5. Recent Developments
  • 8.2. Agensys, Inc.
    • 8.2.1. Overview
    • 8.2.2. Financials
    • 8.2.3. Application Portfolio
    • 8.2.4. Business Strategy
    • 8.2.5. Recent Developments
  • 8.3. Celldex Therapeutics Inc.
    • 8.3.1. Overview
    • 8.3.2. Financials
    • 8.3.3. Application Portfolio
    • 8.3.4. Business Strategy
    • 8.3.5. Recent Developments
  • 8.4. Concortis Biotherapeutics
    • 8.4.1. Overview
    • 8.4.2. Financials
    • 8.4.3. Application Portfolio
    • 8.4.4. Business Strategy
    • 8.4.5. Recent Developments
  • 8.5. F. Hoffmann-La Roche Ltd.
    • 8.5.1. Overview
    • 8.5.2. Financials
    • 8.5.3. Application Portfolio
    • 8.5.4. Business Strategy
    • 8.5.5. Recent Development
  • 8.6. Pfizer Inc.
    • 8.6.1. Overview
    • 8.6.2. Financials
    • 8.6.3. Application Portfolio
    • 8.6.4. Business Strategy
    • 8.6.5. Recent Development
  • 8.7. Sanofi S.A.
    • 8.7.1. Overview
    • 8.7.2. Financials
    • 8.7.3. Application Portfolio
    • 8.7.4. Business Strategy
    • 8.7.5. Recent Development
  • 8.8. Seattle Genetics, Inc
    • 8.8.1. Overview
    • 8.8.2. Financials
    • 8.8.3. Application Portfolio
    • 8.8.4. Business Strategy
    • 8.8.5. Recent Development
  • 8.9. Synthon Holding B.V
    • 8.9.1. Overview
    • 8.9.2. Financials
    • 8.9.3. Application Portfolio
    • 8.9.4. Business Strategy
    • 8.9.5. Recent Development
  • 8.10. Takeda Pharmaceutical Company Limited
    • 8.10.1. Overview
    • 8.10.2. Financials
    • 8.10.3. Application Portfolio
    • 8.10.4. Business Strategy
    • 8.10.5. Recent Development

Table Of Figures

List of Figures

1. Market research process
2. Market research methodology
3. Global Antibody-Drug Conjugates market, 2024-2032 (USD Billion)
4. Porter’s five forces analysis: Antibody-Drug Conjugates market
5. Global Antibody-Drug Conjugates market attractiveness, by application
6. Global Antibody-Drug Conjugates market attractiveness, by Technology
7. Global Antibody-Drug Conjugates market revenue share, by application, 2024 and 2032
8. Global Antibody-Drug Conjugates market revenue share, by Technology, 2024 and 2032
9. Global Antibody-Drug Conjugates market revenue share, by region, 2024 & 2032
10. North America Antibody-Drug Conjugates market, 2024-2032 (USD Billion)
11. Europe Antibody-Drug Conjugates market, 2024-2032 (USD Billion)
12. Asia Pacific Antibody-Drug Conjugates market, 2024-2032 (USD Billion)
13. Latin America Antibody-Drug Conjugates market, 2024-2032 (USD Billion)
14. Middle East & Africa Antibody-Drug Conjugates market, 2024-2032 (USD Billion)

Table Of Tables

List of Tables

1. Global Antibody-Drug Conjugates market: snapshot
2. Drivers for Antibody-Drug Conjugates market: impact analysis
3. Restraints for Antibody-Drug Conjugates market: impact analysis
4. North America Antibody-Drug Conjugates market revenue, by country, 2024-2032 (USD Billion)
5. North America Antibody-Drug Conjugates market revenue, by application, 2024-2032 (USD Billion)
6. North America Antibody-Drug Conjugates market revenue, by Technology, 2024-2032 (USD Billion)
7. The U.S. Antibody-Drug Conjugates market revenue, by application, 2024-2032 (USD Billion)
8. The U.S. Antibody-Drug Conjugates market revenue, by Technology, 2024-2032 (USD Billion)
9. Rest of North America Antibody-Drug Conjugates market revenue, by application, 2024-2032 (USD Billion)
10. Rest of North America Antibody-Drug Conjugates market revenue, by Technology, 2024-2032 (USD Billion)
11. Europe Antibody-Drug Conjugates market revenue, by country, 2024-2032 (USD Billion)
12. Europe Antibody-Drug Conjugates market revenue, by application, 2024-2032 (USD Billion)
13. Europe Antibody-Drug Conjugates market revenue, by Technology, 2024-2032 (USD Billion)
14. U.K. Antibody-Drug Conjugates market revenue, by application, 2024-2032 (USD Billion)
15. U.K. Antibody-Drug Conjugates market revenue, by Technology, 2024-2032 (USD Billion)
16. France Antibody-Drug Conjugates market revenue, by application, 2024-2032 (USD Billion)
17. France Antibody-Drug Conjugates market revenue, by Technology, 2024-2032 (USD Billion)
18. Germany Antibody-Drug Conjugates market revenue, by application, 2024-2032 (USD Billion)
19. Germany Antibody-Drug Conjugates market revenue, by Technology, 2024-2032 (USD Billion)
20. Rest of Europe Antibody-Drug Conjugates market revenue, by application, 2024-2032 (USD Billion)
21. Rest of Europe Antibody-Drug Conjugates market revenue, by Technology, 2024-2032 (USD Billion)
22. Asia Pacific Antibody-Drug Conjugates market revenue, by country, 2024-2032 (USD Billion)
23. Asia Pacific Antibody-Drug Conjugates market revenue, by application, 2024-2032 (USD Billion)
24. Asia Pacific Antibody-Drug Conjugates market revenue, by Technology, 2024-2032 (USD Billion)
25. China Antibody-Drug Conjugates market revenue, by application, 2024-2032 (USD Billion)
26. China Antibody-Drug Conjugates market revenue, by Technology, 2024-2032 (USD Billion)
27. Japan Antibody-Drug Conjugates market revenue, by application, 2024-2032 (USD Billion)
28. Japan Antibody-Drug Conjugates market revenue, by Technology, 2024-2032 (USD Billion)
29. India Antibody-Drug Conjugates market revenue, by application, 2024-2032 (USD Billion)
30. India Antibody-Drug Conjugates market revenue, by Technology, 2024-2032 (USD Billion)
31. Rest of Asia Pacific Antibody-Drug Conjugates market revenue, by application, 2024-2032 (USD Billion)
32. Rest of Asia Pacific Antibody-Drug Conjugates market revenue, by Technology, 2024-2032 (USD Billion)
33. Latin America Antibody-Drug Conjugates market revenue, by country, 2024-2032 (USD Billion)
34. Latin America Antibody-Drug Conjugates market revenue, by Technology, 2024-2032 (USD Billion)
35. Latin America Antibody-Drug Conjugates market revenue, by application, 2024-2032 (USD Billion)
36. Brazil Antibody-Drug Conjugates market revenue, by application, 2024-2032 (USD Billion)
37. Brazil Antibody-Drug Conjugates market revenue, by Technology, 2024-2032 (USD Billion)
38. Rest of Latin America Antibody-Drug Conjugates market revenue, by application, 2024-2032 (USD Billion)
39. Rest of Latin America Antibody-Drug Conjugates market revenue, by Technology, 2024-2032 (USD Billion)
40. Middle  East & Africa Antibody-Drug Conjugates market revenue, by application, 2024-2032 (USD Billion)
41. Middle  East & Africa Antibody-Drug Conjugates market revenue, by Technology, 2024-2032 (USD Billion)